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Endothelial nitric oxide (NO) synthase (eNOS) plays a critical
role in the maintenance of blood vessel homeostasis. Recent
findings suggest that cytoskeletal dynamics play an essential
role in regulating eNOS expression and activation. Here, we
sought to test whether modulation of cytoskeletal dynamics
through pharmacological regulation of histone deacetylase 6
(HDAC6)-mediated tubulin deacetylation affects eNOS expres-
sion and endothelial function in vitro and in vivo. We found that
tubulin acetylation inducer (tubacin), a compound that appears
to selectively inhibit HDAC6 activity, dramatically increased
eNOS expression in several different endothelial cell lines,
as determined by both immunoblotting and NO production
assays. Mechanistically, we found that these effects were not
mediated by tubacin’s inhibitory effect on HDAC6 activity, but
rather were due to its ability to stabilize eNOS mRNA tran-
scripts. Consistent with these findings, tubacin also inhibited
proinflammatory cytokine-induced degradation of eNOS tran-
scripts and impairment of endothelium-dependent relaxation
in the mouse aorta. Furthermore, we found that tubacin-in-
duced up-regulation in eNOS expression in vivo is associated
with improved endothelial function in diabetic db/db mice and
with a marked attenuation of ischemic brain injury in a murine
stroke model. Our findings indicate that tubacin exhibits potent
eNOS-inducing effects and suggest that this compound might
be useful for the prevention or management of endothelial
dysfunction–associated cardiovascular diseases.
Decreased endothelial nitric oxide synthase (eNOS)3 expres-
sion and activity have been implicated in the pathogenesis of a
wide range of cardiovascular conditions, including atheroscle-
rosis, essential hypertension, stroke, and coronary restenosis (1,
2). In healthy blood vessels, the expression of eNOS is tightly
regulated through complex mechanisms, involving transcrip-
tional, post-transcriptional, and post-translational controls (3).
Although eNOS levels fluctuate very little under normal condi-
tions, transcript and protein levels can vary considerably in
response to different types of endogenous or exogenous expo-
sures (4). For instance, the pro-inflammatory agonists TNF,
lipopolysaccharide (LPS), and oxidized low-density lipoprotein
(LDL) down-regulate eNOS expression in endothelial cells (5,
6), whereas the steroid hormone estrogen and HMG-CoA
reductase inhibitors act as potent stimulators of eNOS expres-
sion (7–9). Notably, in many of these scenarios, the fluctuation
in eNOS levels is due to factors that either shorten or prolong
the half-life of eNOS mRNA.
Recently, a growing body of evidence suggests that the
composition of cytoskeletal components can influence the
stability of eNOS mRNA (10). For example, Laufs and others
showed that the half-life of eNOS transcripts can be signifi-
cantly prolonged by physically disrupting the interactions of
actin filaments (11, 12). Moreover, Xue et al. (13) showed
that eNOS transcripts physically interact with microtubule
proteins and that altering the structure of microtubules can
by itself influence eNOS levels and NO production in endo-
thelial cells (11, 14). Taken together, these findings suggest
that pharmacological strategies targeting microtubule pro-
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teins could be employed for manipulating eNOS levels in
cells.
It is now known that post-translational modifications play an
important role in regulating the stability of microtubules (15–
17). Based on this understanding, we hypothesized that manip-
ulating post-translational modifications of tubulin might have
an effect on eNOS levels in endothelial cells. To test this
hypothesis, we focused on the enzyme histone deacetylase 6
(HDAC6), which serves as a potent microtubule-associated
tubulin deacetylase (18, 19), and pharmacological inhibition
of this enzyme is known to regulate acetylation of tubulin
and the stability of microtubules in various types of cells (20,
21). Further, HDAC6 knockout mice are not only viable but
also have normal blood vessel development (22), suggesting
that selective inhibition of HDAC6 might be safe when deliv-
ered systemically (20, 23). In this study, we investigated the
biological effects of tubacin, a compound with selective
HDAC6-inhibitory activity, on the expression of eNOS in
endothelial cells as well as examined the effects of this
compound on NO production and blood vessel functions in
mice.
Results
Tubacin increases eNOS expression in endothelial cells
To investigate the role of HDAC6 in eNOS expression, we
treated HUVECs with tubacin, a compound discovered from
screening over 7000 compounds with an inhibitory effect on
tubulin deacetylation (24, 25). As shown in Fig. 1A, we found
that tubacin dramatically increased eNOS expression in
HUVECs, displaying a maximal effect at 12 h after first expo-
sure. Further, we found that tubacin also increased eNOS
expression in a dose-dependent manner, exhibiting an EC50 of
0.3 mol/liter and showing a maximal effect at a concentra-
tion of 1–2 mol/liter. Consistent with the ability to induce
eNOS expression, we found that NO levels were also markedly
increased in the supernatant of tubacin-exposed cells (Fig. 1, B
and C). As expected, tubacin also appeared to inhibit deacety-
lase activity in our cells, as evidenced by a marked increase in
acetylated tubulin levels. Next, to assess whether the above
findings were specific to HUVECs, we examined the effects
of tubacin on eNOS expression in other EC populations. As
shown in Fig. S1, we found that tubacin induced a similar dose-de-
Figure 1. Tubacin increases eNOS expression and NO generation in HUVECs. A, eNOS expression in HUVECs treated with 1 mol/liter tubacin for
different lengths of time. Protein expression was quantified by densitometry analysis. Results are mean  S.E. (error bars), n  3; *, p  0.05 versus 0 h,
one-way ANOVA with Tukey’s post-test. B, eNOS expression in HUVECs exposed to varying concentrations of tubacin for 12 h. Protein expression was
quantified by densitometric analysis; mean  S.E., n  3; *, p  0.05 versus 0 mol/liter, one-way ANOVA with Tukey’s post-test. C, NO levels in
supernatant of HUVECs treated with varying concentrations of tubacin for 24 h. Results are mean  S.E., n  3; *, p  0.05 versus 0 mol/liter, one-way
ANOVA with Tukey’s post-test.
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pendent increase in eNOS expression in both bovine aortic endo-
thelial cells (BAECs) and primary bovine brain microvascular
endothelial cells (BBMVECs), illustrating the reproducibility of
findings across ECs from different species and vascular beds.
Tubacin induces eNOS expression through HDAC6-
independent mechanisms
Recently, several different HDAC6 inhibitors have been
discovered (20). To assess whether the effects of tubacin on
eNOS expression were specific to this compound, we exposed
HUVECs to several other HDAC6 inhibitors (Fig. 2), including
tubastatin A (selective HDAC6 inhibitor), ACY-1215 (Rocilinos-
tat) (selective HDAC6 inhibitor), and SAHA (vorinostat) (pan-
HDAC inhibitor). We also exposed HUVECs to niltubacin, a com-
pound that is structurally similar to tubacin but lacks any known
HDAC6-inhibitory activity (24). As shown in Fig. 3, we found that
other HDAC6 inhibitors had little or inhibitory effect on eNOS
expression in our cells, although each clearly inhibited deacetylase
activity, as evidenced by the marked increase in acetylated tubulin
levels. In fact, eNOS expression and NO production were actually
reduced in response to tubastatin A and SAHA, but not affected by
ACY-1215, suggesting that effects of tubacin on eNOS might be
independent of actions on HDAC6. Consistent with this line of
reasoning, we found that niltubacin, a compound that lacks
HDAC6-inhibitory activity, also dramatically increased eNOS
expression in our cells. Next, to confirm that tubacin mediates its
effect through HDAC6-independent mechanisms, we performed
siRNA-mediated knockdown of the HDAC6 gene and examined
the effects on eNOS expression. As expected, siRNA knockdown
of HDAC6 markedly reduced mRNA and protein levels of
HDAC6 in our cells (Fig. 4, A and C). Furthermore, we found that
tubacin still readily increased eNOS mRNA and protein levels in
HDAC6-deficient cells (Fig. 4, B–E), supporting the notion that
tubacin augments eNOS expression largely through HDAC6-in-
dependent mechanisms.
Tubacin increases eNOS expression by enhancing eNOS mRNA
stability
Because eNOS mRNA levels were significantly increased
following tubacin exposure, we hypothesized that this might
relate to an increase in gene transcription. To test this, we next
transfected COS-7 cells with a luciferase reporter plasmid linked
to the eNOS promotor (F1: 1600 nucleotides from the transcrip-
tion start site) (26). As shown in Fig. 5, we found that transcription
of eNOS was readily increased in cells exposed to simvastatin,
which has been shown to increase eNOS promoter activity (27). In
contrast, tubacin had little to no effect on gene transcription of
eNOS in our cells (Fig. 5A). Because post-transcriptional mecha-
nisms can also have an influence on eNOS transcript levels, we
next examined whether tubacin acts to prolong the half-life of
eNOS mRNA in our cells. To test this, we inhibited gene transcrip-
tion with actinomycin D and measured transcript levels at various
time points after tubacin exposure. As shown in Fig. 5B, we found
that treatment with tubacin had a dramatic effect on eNOS mRNA
stability, as demonstrated by a doubling of its half-life from 12 to
24 h. Further, we confirmed these findings using a unique reporter
Figure 2. Chemical structure of different HDAC6 inhibitors. Tubacin is a highly selective and reversible HDAC6 inhibitor that permeates the cell membrane.
Tubastatin A and rocilinostat (ACY-1215) are also selective HDAC6 inhibitors. SAHA is a pan-HDAC inhibitor. Niltubacin, which retains the bulk of the chemical
structure of tubacin, but lacks HDAC6-inhibitory activity, is normally used as a negative control for studies with tubacin.
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system in which the luciferase gene was linked to the 3-UTR of
eNOS (Fig. 5C) as we reported previously (28).
In recent work, we reported that the cytoplasmic proteins
eEF1A and PTBP1 play a crucial role in regulating the stability of
eNOS mRNA in ECs (28, 29). To assess whether tubacin alters the
expression of these proteins, we compared levels of eEF1A and
PTBP1 between control and tubacin-exposed cells. Although
tubacin was found to have little to no effect on total protein levels
of either protein (Fig. 5D), we detected a substantial reduction in
cytoplasmic levels of PTBP1 in our cells (Fig. 5E). Because the
binding of cytoplasmic PTBP1 to the eNOS 3-UTR is known to
facilitate mRNA degradation (28), we hypothesized that tubacin
might also act to reduce this protein-transcript interaction. To test
this, we immunoprecipitated PTBP1 from the cytoplasmic frac-
tion of control and tubacin-exposed cells and quantified eNOS
transcript levels in this protein fraction. Consistent with our pro-
posed hypothesis, we found that eNOS transcript levels were
markedly reduced in PTBP1 immunocomplexes after tubacin
exposure (Fig. 5F).
Tubacin ameliorates TNF-induced endothelial dysfunction
through increasing eNOS expression
The pro-inflammatory cytokine TNF is known to cause
endothelial cell dysfunction, in part, by targeting eNOS mRNA
for degradation (28, 29). With this in mind, we next sought to
determine whether tubacin can mitigate eNOS mRNA degra-
dation in response to TNF exposure. Consistent with previous
reports (28, 29), we found that eNOS expression and NO pro-
duction were dramatically reduced in TNF-exposed cells (20
ng/ml) and this was associated with a decrease in eNOS mRNA
stability. Conversely, we found that eNOS expression, NO pro-
duction, and the half-life of eNOS transcripts were markedly
increased in cells treated with tubacin (Fig. 6, A–C). Because
down-regulation of eNOS expression is known to contribute to
endothelial dysfunction in various model systems, we next
sought to determine whether augmenting eNOS expression
with tubacin could restore vascular function in TNF-exposed
blood vessels. After confirming that tubacin (1 mol/liter) can
restore eNOS expression in the isolated mouse aorta after
TNF exposure (20 ng/ml), we examined whether this associ-
ated with improved acetylcholine (Ach)-mediated vasorelax-
ation. As shown in Fig. 6D, we found that treatment with tuba-
cin largely reversed TNF-induced endothelial dysfunction in
isolated aorta segments. As expected, tubacin did not have an
effect on vasodilatory responses to sodium nitroprusside (Fig.
6E), supporting the notion that tubacin’s effects are mediated
specifically through augmenting eNOS expression.
Tubacin enhances endothelium-dependent vasorelaxation in
murine aorta
To examine whether tubacin mediates similar effects in vivo,
we next treated mice with a one-time intraperitoneal injection
Figure 3. The effects of different HDAC inhibitors on eNOS expression in HUVECs. Protein levels of eNOS, acetylated tubulin (Ac-tubulin), total tubulin, and
GAPDH in HUVECs treated with tubastatin (A), ACY-1215 (B), SAHA (C), or niltubacin (D) for 24 h. Representative images of Western blots (top) and densitometry
measures (bottom) are shown. Results are mean  S.E. (error bars), n  3; *, p  0.05 versus 0 mol/liter, one-way ANOVA with Tukey’s post-test. E–G, NO levels
in the supernatant of HUVECs treated with varying concentrations of tubastatin, ACY-1215, or SAHA for 24 h. Results are mean  S.E., n  3; *, p  0.05 versus
0 M, one-way ANOVA with Tukey’s post-test.
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of tubacin (5 mg/kg) or vehicle control and examined eNOS
expression in the mouse aorta. As shown in Fig. 7 (A and B), we
found that both mRNA and protein levels for eNOS were sig-
nificantly increased in the aorta of tubacin-treated mice. More-
over, this was associated with a substantial reduction in cyto-
plasmic levels of PTBP1 (Fig. 7C) and a weak, but significant,
increase in Ach-induced vasorelaxation (Fig. 7D). Importantly,
in the presence of a NOS inhibitor (NG-nitro-L-arginine methyl
ester) or NO donor sodium nitroprusside, tubacin’s effects on
Ach-mediated vasorelaxation were largely abolished (Fig. 7, D
and E), indicating that tubacin mediates its effects on blood
vessel tone via eNOS-dependent mechanisms.
To determine whether tubacin is able to attenuate endothe-
lial dysfunction in disease, we employed db/db mice, which are
known to manifest an impaired endothelial function at 4
months of age (30). Using these mice, we found that treatment
with tubacin (5 mg/kg/day, intraperitoneally, 1 week) signifi-
cantly improved endothelium-dependent vasorelaxation to
ACh in aortas of db/db mice (Fig. 8A) and the expression of
eNOS, as determined by Western blotting (Fig. 8B). Consistent
with a previous report (31), Ach-mediated vasorelaxation in the
aorta of eNOS knockout mice was significantly impaired, which
was not affected by tubacin treatment (Fig. 8C), further illus-
trating the vasoprotective effects of tubacin in vivo through
eNOS-dependent mechanisms.
Tubacin attenuates cerebral injury in mice
Finally, because NO is known to have potent neuroprotective
and anti-apoptotic properties (11, 32), we hypothesized that
tubacin might reduce brain injury in a cerebral ischemia model.
To this end, we employed the well-established mouse middle
cerebral artery occlusion (MCAO) model to assess the effects of
tubacin on ischemia-induced brain injury. As shown in Fig. 9,
we found that pretreatment with tubacin (5 mg/kg) signifi-
cantly reduced cerebral infarct size and the severity of cortical
edema at 24 h after arterial occlusion (Fig. 9, A and B) when
compared with controls. Consistent with a reduction in brain
injury, we found that functional neurological scores were also
significantly improved in tubacin-treated mice (Fig. 9C). More-
over, these findings were associated with a marked increase in
eNOS expression in the ischemic penumbra at 24 h after
MCAO (Fig. 9D), supporting the concept that tubacin mediates
its effects by augmenting eNOS expression.
Discussion
In this study, we show that tubacin acts to increase eNOS
expression and NO production in vitro and in vivo. However, in
contrast to previous reports, we found that tubacin does not
mediate its effects through inhibiting HDAC6 activity but
rather through stabilizing eNOS mRNA. Because many patho-
logical conditions are known to decrease eNOS expression in
endothelial cells by reducing mRNA stability (5, 6, 28, 29), iden-
tification of tubacin as a potent eNOS enhancer suggests that
tubacin or its analogues might be effective in ameliorating sys-
temic vascular complications of disease. Along these lines, we
found that tubacin ameliorated endothelial dysfunction in a
mouse diabetic model and reduced the size of cerebral infarc-
Figure 4. Tubacin-induced eNOS expression occurs independent of HDAC6 inhibition. A and B, transcript levels for HDAC6 or eNOS in control and
HDAC6-deficient cells exposed to varying concentrations of tubacin for 6 h. C, protein levels for eNOS, acetylated -tubulin, total -tubulin, HDAC6, and GAPDH
in control and HDAC6-deficient cells exposed to different concentrations of tubacin for 24 h. D, densitometry measurements of eNOS and HDAC6 in control and
HDAC6-deficient cells exposed to different concentrations of tubacin for 24 h. E, NO levels in supernatants of HUVECs exposed to 0 –2 mol/liter tubacin for
24 h. Results are mean  S.E. (error bars), n  3; *, p  0.05 versus 0-h control siRNA, one-way ANOVA with Tukey’s post-test; #, p  0.05 versus 0-h HDAC6 siRNA,
one-way ANOVA with Tukey’s post-test.
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tion in mice after transient occlusion of the middle cerebral
artery.
The interplay between histone deacetylases (HDACs) and
histone acetyltransferases differentially regulates the acetyla-
tion status of histone and nonhistone proteins and regulates
gene expression in various ways (33, 34). In addition to regulat-
ing gene expression, HDACs are also involved in a number of
other important biological pathways, including those involved
in growth, proliferation, and differentiation of cells (35, 36).
Indeed, in the vessel wall, several HDACs have been identified
to regulate eNOS through both transcriptional and post-trans-
lational mechanisms (37, 38). For example, at post-translational
levels, both HDAC1 and HDAC3 have been shown to induce
lysine deacetylation of eNOS, thereby inhibiting eNOS activity
(38). Furthermore, treatment of endothelial cells with pan-
HDAC inhibitors, such as trichostatin A and butyric acid, has
been shown to decrease eNOS expression at post-transcrip-
tional levels through yet unidentified mechanisms (37). Con-
sistent with the previous report (37), we found that tubastatin A
(selective HDAC6 inhibitor) and SAHA (pan-HDAC inhibitor)
reduced eNOS protein expression in HUVECs. Recent studies
have demonstrated that modulation of the endothelial actin
cytoskeleton represents a major mechanism in regulating
eNOS expression and mRNA stability (39, 40). Among 18
HDACs in mammals, HDAC6 is a unique member of the type II
HDACs that has been shown to regulate cytoskeleton dynamics
by acting as a specific -tubulin deacetylase (18, 22), which
prompted us to investigate whether inhibition of HDAC6 could
alter eNOS gene expression through modulating cytoskeleton
dynamics in endothelial cells. In the present study, we treated
endothelial cells with three structurally unrelated inhibitors of
HDAC6 and found that only tubacin potently increased eNOS
expression, despite all three inhibitors exhibiting inhibitory
effects on -tubulin deacetylation. Furthermore, we found that
niltubacin, an inactive tubacin analog without inhibitory effect
on HDAC6, also increased eNOS protein expression in a dose-
dependent manner, with no changes on the acetylated levels of
-tubulin. Most importantly, our experiments performed in
HDAC6 knockdown cells demonstrated that eNOS expression
increased by tubacin was largely, if not wholly, independent of
HDAC6, as tubacin increased eNOS expression to a similar
extent in control siRNA– and HADC6 siRNA–transfected
cells. Together, these results identified tubacin as a unique
compound that potently increases eNOS expression and NO
production through mechanisms independent of its effects on
HDAC6.
Endothelially derived NO is a critical mediator of vascular
integrity (41). Although the expression of eNOS is regulated at
multiple levels, it has been increasingly appreciated that post-
transcriptional regulation plays an important role (40). Our
Figure 5. Tubacin increases eNOS mRNA stability in HUVECs. A, relative luciferase activity in COS-7 cells treated with tubacin or 5 mol/liter simvastatin for
12 h. Cell lysates were assayed for luciferase activities. Results are mean  S.E. (error bars), n  3. B, eNOS transcript levels in HUVECs treated with or without 1
M tubacin for 3 h. eNOS mRNA stability was determined by exposing cells to 5 M actinomycin D. Results are mean  S.E., n  3. C, relative luciferase activity
in COS-7 cells treated with different concentrations of tubacin. Results are mean  S.E., n  3; *, p  0.05 versus 0 mol/liter, one-way ANOVA with Tukey’s
post-test. D, the protein levels of PTBP1 and eEF1A in HUVECs treated with different concentrations of tubacin for 24 h. E, PTBP1 and eEF1A levels in the
cytoplasmic or nuclear fraction of HUVECs treated with either vehicle or 1 mol/liter tubacin for 24 h. GAPDH was used as a cytoplasmic marker, and histone
3 was used as a nuclear marker. F, eNOS mRNA levels in the anti-PTBP1 immunoprecipitates were quantified by real-time PCR of control and tubacin-treated
cells. Data are shown as enrichment over the control IgG antibody. Results are mean  S.E., n  3; *, p  0.05 versus control, unpaired Student’s t test.
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laboratory has recently reported that PTBP1, also known as
hnRNP1 (heterogeneous nuclear ribonucleoprotein 1), is an
essential trans-acting factor that binds to eNOS 3-UTR in the
cytoplasm, leading to eNOS mRNA destabilization and impair-
ment of endothelium-dependent vasorelaxation (28). In our
study, we found that tubacin up-regulated eNOS expression, in
part, through suppressing cytoplasmic PTBP1 levels in endo-
thelial cells. At this point, the molecular mechanism underlying
tubacin-mediated suppression of PTBP1 remains unknown.
PTBP1 is a nucleocytoplasmic shuttling protein that has been
shown to regulate RNA metabolism, including mRNA stability,
translation, and localization (42, 43). For example, glucose
stimulation of pancreatic beta cells can induce redistribution of
PTBP1 from the nucleus to the cytoplasm, thus promoting
PTBP1 binding to 3-UTR of insulin to enhance mRNA stability
(44). Interestingly, PTBP1 has been shown to bind to the
mRNAs of actin and the focal adhesion proteins vinculin and
-actinin 4 to regulate cytoskeletal assembly (45, 46). Thus, it is
tempting to speculate that tubacin may increase eNOS expres-
sion through at least two mechanisms, which include the dis-
ruption of PTBP1 binding to eNOS 3-UTR and the inhibition
of PTBP1-mediated cytoskeleton assembly. Further, it would
be interesting to investigate whether tubacin can also regulate
nucleocytoplasmic shuttling of PTBP1 by affecting its phos-
phorylation status, as reported previously in the neuronal PC12
cells (47).
Vascular NO production regulates cerebrovascular perfu-
sion and protects against stroke by increasing collateral flow to
the ischemic area (48, 49). In general, preclinical studies dem-
onstrate that NO generated by the neuronal and inducible NOS
after stroke is detrimental to neuronal survival (30), whereas
eNOS and endothelial NO are neuroprotective (49). Mice lack-
ing eNOS exhibit larger cerebral infarctions, and further inhi-
bition of NOS activity by N-nitro-L-arginine methyl ester
(L-NAME) increases infarct size (11, 48, 50). In contrast, up-
regulation of eNOS by estrogen, statins, and Rho kinase inhib-
itors has consistently been shown to confer protection from
ischemic stroke in mice (8, 51). Therefore, conditions that
enhance eNOS activity could have beneficial effects on cerebro-
vascular disease. In our study, we show that treatment of mice
with tubacin for only 2 days prior to ischemic injury markedly
reduced infarct size and brain edema after MCAO. Further-
more, our findings suggest that vascular protective effects of
tubacin might be mediated through its ability to increase eNOS
expression. This was suggested based on finding elevated eNOS
levels in the ischemic penumbra and our other findings show-
ing that tubacin’s effects on vessel relaxation were dependent
on the expression of eNOS. Interestingly, the increased relaxing
Figure 6. Tubacin inhibits TNF-induced down-regulation of eNOS in HUVECs and ameliorates TNF-induced endothelial dysfunction in the aorta of
mice. A, protein levels of eNOS in HUVECs treated with or without TNF (20 ng/ml) in the presence or absence of tubacin. Results are mean  S.E. (error bars),
n  3; *, p  0.05, one-way ANOVA with Tukey’s post-test. B, NO levels in the supernatant of HUVECs pretreated with 1 mol/liter tubacin for 1 h and then
exposed to vehicle or 20 ng/ml TNF for 24 h. Results are mean  S.E. n  3; *, p  0.05, one-way ANOVA with Tukey’s post-test. C, eNOS mRNA half-life in
control and tubacin-treated cells exposed to PBS versus TNF. The data are representative of five independent experiments. D, Ach-induced endothelium-de-
pendent relaxation in aortas treated with or without tubacin (1 mol/liter) for 24 h while also being exposed to control or TNF. Endothelium-dependent
vasorelaxation was determined by measuring Ach-induced relaxation in rings precontracted with phenylephrine. Endothelium-dependent vasorelaxation was
determined by measuring Ach-induced relaxation in rings precontracted with phenylephrine; n  8; *, p  0.05 versus control group at 105 mol/liter
acetylcholine; #, p  0.05 versus TNF group at 105 mol/liter acetylcholine, one-way ANOVA with Tukey’s post-test. E, endothelium-independent vasorelax-
ation to sodium nitroprusside (SNP) was examined.
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response to acetylcholine in normal mice is relatively week.
This is not surprising because eNOS gene expression and the
resulting content of eNOS protein is not a limiting factor under
normal conditions (i.e. in the absence of endothelial dysfunc-
tion). In fact, this effect is more remarkable in db/db mice, indi-
cating that tubacin is capable of restoring altered eNOS expres-
sion under pathological conditions.
Several lines of evidence suggest that HDAC6 is essentially
involved in the development of cancer and neurodegenerative
disorders, such as Parkinson disease and Huntington disease
(20, 23, 52, 53). Thus, HDAC6 has emerged as a promising
therapeutic target for treatment of these diseases. Investigation
of HDAC6 inhibitors on eNOS expression is not only important
to identify eNOS regulators, but also allows us to predict
Figure 7. The effect of tubacin on eNOS expression and endothelium-dependent relaxation in mice. Mice were intraperitoneally injected with 5 mg/kg
tubacin. 24 h after injection, the eNOS protein levels (A) and eNOS mRNA levels (B) in mouse aorta were measured by Western blotting and qRT-PCR,
respectively. Results are mean  S.E. (error bars), n  3– 4; *, p  0.05 versus control group, unpaired Student’s t test. C, the levels of PTBP1 in cytosolic and
nuclear subcellular fractions were determined by Western blotting in mouse aorta treated with or without tubacin for 24 h. GAPDH was used as a cytoplasmic
marker, and histone 3 was used as a nuclear marker. D, representative traces of Ach-induced endothelium-dependent relaxations in aortas from mice treated
with or without tubacin for 24 h. Endothelium-dependent vasorelaxation was determined by measuring Ach-induced relaxation in rings precontracted with
phenylephrine; n  8; *, p  0.05 versus control group at 105 mol/liter acetylcholine, one-way ANOVA with Tukey’s post-test. E, endothelium-independent
vasorelaxation to sodium nitroprusside (SNP) was examined.
Figure 8. Tubacin improves endothelial function in diabetic mice. A, db/db mice received intraperitoneal injection of either vehicle or 5 mg/kg/day of
tubacin for a week, and Ach-induced endothelium-dependent relaxation of aortic ring was determined. Results are mean  S.E. (error bars); n  8; *, p  0.05
versus vehicle at 105 mol/liter acetylcholine, one-way ANOVA with Tukey’s post-test. B, db/db mice received intraperitoneal injection of either vehicle or 5
mg/kg/day of tubacin for a week. Expression of eNOS was determined by Western blotting. n  3; *, p  0.05 versus vehicle control group, unpaired Student’s
t test. C, eNOS knockout (KO) mice received intraperitoneal injection of vehicle or 5 mg/kg/day of tubacin for a week, and Ach-induced endothelium-dependent
relaxation of aortic ring was determined. n  8.
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potential side effects of these inhibitors in the cardiovascular
system. Tubastatin was previously shown to have selectivity
and potency similar to those of tubacin in inhibiting HDAC6
activity (54), but we found that each exerted opposite effects on
eNOS expression. Moreover, we found that rocilinostat (ACY-
1215), which is structurally similar to tubacin (55), had no effect
on eNOS expression. In this regard, it is tempting to speculate
that in vivo application of tubastatin may lead to cardiovascular
complications through inhibiting eNOS activity, as compared
with other inhibitors, such as tubacin and rocilinostat.
In conclusion, we provide compelling evidence that tubacin
is a potent eNOS enhancer and can induce the production of
NO both in vitro and in vivo as well as exert vascular protective
effects in various clinical scenarios. Importantly, we found that
these unique activities were independent of its HDAC6 inhibitor
effects and related more to its ability to selectively increase eNOS
mRNA stability. Despite its high lipophilicity and difficulties in
synthesis, successful identification of tubacin as a promising vaso-
protective agent suggests that further optimizing its structure for
in vivo use might be worthwhile because of its potential as a treat-
ment for a wide range of cardiovascular diseases.
Experimental procedures
Cell culture
HUVECs were purchased from ATCC and cultured in
EBM-2 Basal Medium (Lonza) supplemented with EGM-2
BulletKit (Lonza). COS-7 cells and BAECs were also purchased
from ATCC but cultured in Dulbecco’s modified Eagle’s
medium. BBMECs were purchased from Lonza and grown in
EBM-2 basal medium (Lonza) supplemented with EMVB
SingleQuots (Lonza). In some studies, endothelial cells were
exposed to tubacin (Tocris Bioscience), tubastatin A (Tocris
Bioscience), ACY-1215 (Cayman Chemical), or vorinostat
(Cayman Chemical). Niltubacin (Enzo Life Sciences) served as a
negative control in HDAC6 inhibitor experiments.
Gene silencing with small interference RNA
Human HDAC6 and scrambled (Mission siRNA Universal
Negative Control) siRNA were transfected into HUVECs using
the Lipofectamine RNAiMAX transfection Reagent (Invitro-
gen) according to the manufacturer’s recommendations.
Quantitative real-time PCR (qRT-PCR)
Total RNA was extracted using the TRIzol reagent kit (Invit-
rogen). qRT-PCR analysis was performed as we described pre-
viously (56). Briefly, cDNA was synthesized from total RNA
using the High-Capacity cDNA Archive Kit (Applied Biosys-
tems). qRT-PCR was performed using the MyiQTM single-
color real-time PCR detection system (Bio-Rad) and Hot-
Start-IT SYBR Green one-step qRT-PCR master mix kit (AB
Science).
Luciferase assay
COS-7 cells were transfected with the firefly luciferase
F1-eNOS-promoter reporter plasmid or firefly luciferase-
eNOS-UTR reporter plasmid, together with control luciferase
Figure 9. Tubacin reduces cerebral infarct size, improves neurological function, and increases eNOS expression in MCAO mice. A, representative
TTC-stained cerebral sections of the MCAO model showing decrease infarct size (white area) in tubacin-treated mice as compared with the vehicle-treated
group. B and C, quantitative measurement of infarct size and cerebral edema in control and tubacin-treated mice after MCAO. n  6 –7 for each group; **, p 
0.01, unpaired Student’s t test. D, neurological deficit scores in control and tubacin-treated mice at 24 h after MCAO. Data are presented as mean  S.E. (error
bars) n  6 –7 for each group; **, p  0.01, unpaired Student’s t test. E, eNOS protein levels in brain penumbra after reperfusion for 24 h. Densitometry
measurements are depicted in a bar graph. Each bar represents the mean  S.E. n  3; *, p  0.05 compared with vehicle-treated group, one-way ANOVA with
Tukey’s post-test; #, p  0.05 compared with the sham group, one-way ANOVA with Tukey’s post-test.
Tubacin mediates vascular protection













reporter plasmid (28, 29). 24 h after transfection, cells were
incubated with tubacin or simvastatin (eNOS-inducing agent)
for an additional 24 h. Cell lysates were then collected and
assayed for luciferase activity using the Dual-Luciferase assay
system (Promega).
Determination of eNOS mRNA stability
The effects of tubacin on eNOS mRNA stability were deter-
mined by comparing mRNA levels in control and actinomycin
D (5 M)-exposed cells. -Fold change in gene expression was
calculated using the 2CT method with 18S rRNA as an inter-
nal control as described previously (28). The relative amount of
eNOS mRNA at 0 h AcD was set at 100%.
Western blot analysis
Western blot analysis was performed as described previously
(28). In brief, cell lysates were resolved by SDS-PAGE and trans-
ferred to nitrocellulose membrane (Bio-Rad). Blots were incu-
bated with diluted primary antibodies against histone 3 (Santa
Cruz Biotechnology, Inc., 10809, 1:1000), GAPDH (Santa Cruz
Biotechnology, 32233 and 25778, 1:1000), -tubulin (Cell Sig-
naling, 2144, 1:2000), acetylated -tubulin (Cell Signaling,
3971, 1:1000), HDAC6 (Cell Signaling, 7558, 1:500) and eNOS
(BD Biosciences, 610297, 1:500), PTBP1 (Abcam, ab5642,
1:1000), eEF1A (Thermo Fisher Scientific, PA5-17213, 1:1000)
followed by either IRDye 700 – or 800 –labeled secondary anti-
bodies (1:10,000, LI-COR, 926-32212, 926-68073, and 925-
68074) and then were visualized on an Odyssey Imaging System
(LI-COR).
Measurement of NO production
The NO production was assessed by quantifying nitrite and
nitrate levels in the supernatant of cells. Nitrite (NO2) and
nitrate (NO3) levels were determined using a chemilumines-
cence NO detector (Siever 280i NO Analyzer), as described
previously (57).
Preparation of nuclear and cytoplasmic extracts
HUVECs were lysed in hypotonic buffer (20 mM Tris-HCl,
pH 7.4, 10 mM NaCl, 3 mM MgCl2, 100 units of RNase OUT
(Invitrogen), protease inhibitor mixture (Roche Applied Sci-
ence)) on ice for 15 min, and then 25 l of detergent (10%
Nonidet P-40) was added. The mixture was vortexed for 10 s,
followed by centrifugation at 3000 rpm for 10 min at 4 °C. After
centrifugation, the supernatant was removed and represents
the cytoplasmic fraction for Western blotting and RNA Immu-
noprecipitation. Nuclear extract was suspended by Cell Extrac-
tion Buffer (10 mM Tris-HCl, pH 7.4, 100 mM NaCl, 10% glyc-
erol, 1% Triton X-100, 1 mM EDTA, 0.1% SDS mixture) with
protease inhibitors, followed by centrifugation at 16,000 rpm
for 30 min at 4 °C.
RNA immunoprecipitation
Cytoplasmic fraction was incubated with 4 g of anti-PTBP1
mAb (Abcam) 2 h at 4 °C and 20 l of Protein A/G (Santa Cruz
Biotechnology) to perform immunoprecipitation. Immune
complexes were then washed multiple times with hypotonic
buffer, total RNA was extracted using the TRIzol reagent (Invit-
rogen), and eNOS mRNA levels were quantified by qRT-PCR
(29).
Arterial ring preparation and vascular tension recording
Studies were performed in accordance with the Guide for the
Care and Use of Laboratory Animals published by the National
Institutes of Health following protocols that were reviewed and
approved by the Institutional Animal Care and Use Committee
at Thomas Jefferson University. All experiments were per-
formed on adult (8 –12-week-old) male C57BL/6J mice, male
eNOS knockout mice (stock no. 002684, Jackson Laboratory,
Bar Harbor, ME), and male BKS-db/db mice (stock no. 000642,
Jackson Laboratory). All animals were euthanized by carbon
dioxide. Experimental mice were randomized to receive either
5 mg/kg tubacin or DMSO by intraperitoneal injection. 24 h
after injection, mice were sacrificed, and segments of the
descending aorta were recovered. Aortic tissues were main-
tained in ice-cold Krebs–Henseleit buffer consisting of 118 mM
NaCl, 25 mM NaHCO3, 4.5 mM KCl, 1.2 mM KH2PO4, 1.2 mM
MgSO4, 2.5 mM CaCl2, and 11 mM glucose. Loose fat and con-
nective tissue were removed, and 2–3-mm aorta rings were
isometrically mounted on a Multi-Wire Myograph System
(DMT620M). Resting tension for each aortic ring was set at 4
millinewtons and maintained at this level throughout the
experiment. During equilibration, the rings were exposed to
Krebs–Henseleit buffer (replaced every 15 min) at 37 °C and
continuously gassed with 95% O2, 5% CO2. After 2 h, rings were
exposed to phenylephrine (1 	 106 M) to elicit contraction,
followed by monitoring of endothelium-dependent vasorelax-
ation to acetylcholine (109 to 105 M) over time. eNOS-inde-
pendent vasorelaxation was assessed by measuring the cumu-
lative response to acetylcholine in rings pretreated with the
eNOS inhibitor L-NAME (104 M). Endothelium-independent
vasorelaxation was measured by assessing response to sodium
nitroprusside (1010 to 106 M). Data were analyzed using
the Powerlab system (AD Instruments). Vasorelaxation was
expressed as a percentage based on the percentage change from
the preconstricted state.
MCAO model
Both male and female mice (12 weeks old) were injected with
either vehicle (DMSO) or tubacin (5 mg/kg, intraperitoneally)
twice at 24 and 3 h, respectively, before surgical occlusion. Focal
cerebral ischemia was induced by transient MCAO as previ-
ously described (58). Animals were randomly divided into three
groups: the sham group, the MCAO with vehicle-treated group,
and the MCAO with tubacin-treated group. In the tubacin-
treated group, 5 mg/kg tubacin was intraperitoneally injected
3 h before MCAO. Mice were subjected to MCAO by transient
right MCA occlusion (60 min) under isoflurane (3%) anesthe-
sia, followed by 24 h of reperfusion. Body temperature was con-
trolled at 37 °C. Occlusion and reperfusion were verified in each
animal by laser speckle contrast imaging (Pericam PSI). All ani-
mals were euthanized by carbon dioxide. For the quantification
of infarct size, brain tissue was collected at 24 h for standard
2,3,5-triphenyltetrazolium chloride (TTC) histology and digital
image analysis of infarct volume. Neurological function was
evaluated using a 0 – 4-point neurological score: 0  no neuro-
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logical dysfunction; 1  failure to extend left forelimb fully
when lifted by tail: 2  circling to the contralateral side; 3 
falling to the left; 4  no spontaneous walk or in a comatose
state, or barrel rolling. All scores were performed while blinded
to study groups.
Statistical analysis
All values are expressed as the mean  S.E. Comparisons
between two groups were analyzed by t test, whereas compari-
sons between more than two groups were made using one-way
ANOVA followed by Tukey’s post-test. p  0.05 was consid-
ered statistically significant. All statistical analyses were per-
formed via GraphPad Prism version 5.
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